Zai Lab (NASDAQ:ZLAB) is a Shanghai-based, biopharmaceutical company focused on discovering and developing innovative therapies for cancer, autoimmune disorders, and infectious diseases. Founded in 2014, the company operates with dual headquarters in Shanghai and the San Francisco Bay Area, reflecting its commitment to bridging the gap between China’s rapidly expanding healthcare market and global innovation hubs. Zai Lab’s mission centers on advancing cutting-edge science into accessible treatments for patients worldwide.
The company’s business model combines in-licensing of late-stage assets with the internal discovery of novel compounds. Zai Lab has established partnerships with leading multinational biopharmaceutical firms to commercialize approved oncology products in Greater China, while simultaneously progressing a proprietary pipeline through clinical development across multiple therapeutic areas. Their approach leverages local regulatory expertise, clinical operations, and manufacturing capabilities to accelerate time to market in China, complemented by global collaborations to ensure broader patient access.
With research and development centers in Shanghai and Cambridge, Massachusetts, Zai Lab conducts early- and late-stage clinical trials under both U.S. Food and Drug Administration and China National Medical Products Administration guidelines. The company’s portfolio spans small molecules, biologics, and antibody-drug conjugates, reflecting a diversified strategy aimed at high-unmet-need indications. In addition to oncology, Zai Lab is advancing programs in immunology and infectious disease, positioning itself to address evolving healthcare challenges in diverse geographies.
Leadership at Zai Lab is spearheaded by co-founder and Chief Executive Officer Samantha Du, Ph.D., whose experience includes senior roles at global pharmaceutical companies and leading biotech ventures. Supported by an executive team with deep expertise in drug development, regulatory affairs, and commercialization, the company continues to build its capabilities in strategic licensing, clinical operations, and market access. Zai Lab’s growing presence in both China and the United States underscores its role as a pivotal player in the international biopharmaceutical landscape.
